GSK locks in ViiV Healthcare majority as Shionogi doubles down and Pfizer exits with $1.8bn

GSK plc (LSE/NYSE: GSK) has completed the restructuring of its ViiV Healthcare Limited shareholder base, with Pfizer Inc. (NYSE: PFE) fully exiting an investment it held since ViiV Healthcare was established in 2009 and Shionogi & Co., Ltd (TYO: 4507) more than doubling its economic interest to 21.7%. The transaction, which closed on 1 April 2026, involved ViiV Healthcare issuing new shares to Shionogi for $2.125 billion and simultaneously cancelling Pfizer’s 11.7% holding. Pfizer received $1.875 billion in proceeds, while GSK received a special dividend of $250 million paid in British pounds. GSK now holds 78.3% of ViiV Healthcare and Shionogi holds the remaining 21.7%, a simplified two-party structure that removes a counterparty whose strategic interests in HIV had long since diverged from those of its co-shareholders.

The deal follows the January 2026 agreement between the three parties and completes within the Q1 2026 timeframe that GSK had committed to when the transaction was first announced. For GSK, the clean-up of the cap table is not merely administrative. ViiV Healthcare is one of the most profitable units within the GSK portfolio, with HIV sales running at roughly £5.5 billion in the first nine months of 2025 out of total GSK group revenue of just over £24 billion over the same period. GSK has stated an ambition to grow ViiV’s full-year sales past the £7 billion mark, a target underpinned by the accelerating commercial trajectory of its long-acting injectable portfolio.

Why did Pfizer exit ViiV Healthcare and what does the $1.875 bn sale price tell us about the asset’s valuation?

Pfizer’s exit from ViiV Healthcare has been anticipated for years. The New York-based pharmaceutical group has been in strategic retreat from non-core assets since its own R&D prioritisation shifted firmly toward oncology, vaccines, and antiviral platforms during and after the COVID-19 period. A minority stake in a competitor-managed HIV joint venture, with limited board influence and no operational control, offered Pfizer diminishing strategic returns relative to the capital it had tied up. The $1.875 billion that Pfizer received for an 11.7% stake implies an enterprise value for ViiV Healthcare of approximately $16 billion, a figure that sits broadly in line with analyst estimates given ViiV’s annualised revenue trajectory and the growth premium attached to its long-acting pipeline.

The decision to structure the transaction as a share cancellation rather than a secondary sale to Shionogi also carries tax and accounting significance. By issuing fresh shares to Shionogi rather than transferring Pfizer’s existing holding, ViiV Healthcare crystallised a clean transaction for both seller and acquirer without creating secondary market exposure or triggering the complications that can arise when a minority investor in a private entity tries to sell its stake to a third party. GSK’s balance sheet also benefits from the extinguishment of the Pfizer put option liability that had been carried in its accounts for the year ended 31 December 2025, removed through retained earnings at completion with any fair value movement recognised as an adjusting item through other operating income.

What does Shionogi’s decision to increase its ViiV Healthcare stake to 21.7% signal about its HIV strategy?

Shionogi’s willingness to commit $2.125 billion to increase its economic interest from 10% to 21.7% is a statement of strategic conviction at a pivotal moment in the HIV therapy market. The Osaka-based company has had a long relationship with ViiV Healthcare dating to the formation of the joint venture, and its scientists contributed to the discovery of cabotegravir, the integrase strand transfer inhibitor that underpins Cabenuva, ViiV’s flagship long-acting injectable treatment. By deepening its financial stake, Shionogi is not just investing in current revenues but placing a substantial bet on the long-acting HIV franchise at precisely the moment that competition is intensifying.

Shionogi’s HIV division is already one of its most important strategic focus areas, and this transaction aligns the capital commitment to that stated priority. The increased stake also means Shionogi will receive a larger share of ViiV Healthcare’s royalty and profit distributions, providing a more significant recurring revenue stream to complement its own drug discovery operations. The structure of the deal, in which Shionogi paid a modest premium above Pfizer’s exit price to acquire an asset with a growing earnings base, reflects considered capital allocation rather than opportunistic buying.

How is ViiV Healthcare’s long-acting HIV portfolio performing commercially against the Gilead Sciences lenacapavir challenge?

The backdrop against which this ownership change has been completed is a HIV market undergoing one of its more consequential strategic transitions. Cabenuva, the monthly injectable HIV treatment combining cabotegravir and rilpivirine, generated approximately £1.4 billion in annual sales in 2025, representing 55% of ViiV Healthcare’s total HIV growth for the year. Apretude, the long-acting injectable option for HIV prevention dosed every two months, has further expanded the portfolio’s commercial footprint. Together, the long-acting portfolio is tracking toward exceeding £2 billion in sales in 2026, which ViiV Healthcare has projected would represent roughly one-third of its total HIV revenue.

The competitive pressure, however, is not trivial. Gilead Sciences has entered the long-acting arena with lenacapavir, a capsid inhibitor that offers twice-yearly dosing as both a treatment for multidrug-resistant HIV and as a pre-exposure prophylaxis option. In the PrEP segment, ViiV Healthcare’s Apretude, dosed every two months, is competing directly with Gilead’s Yeztugo/Yeytuo. The frequency differential matters clinically and commercially because patients and healthcare providers increasingly value the fewest possible injections per year. Gilead’s twice-yearly dosing interval for lenacapavir represents a genuine challenge to Apretude’s positioning, and how that competitive dynamic resolves over the next several years will significantly shape ViiV Healthcare’s revenue trajectory and, by extension, the value of the stake Shionogi has just paid $2.125 billion to hold.

How does the simplified ViiV Healthcare ownership structure affect GSK’s balance sheet and dividend capacity?

For GSK, the removal of Pfizer as a shareholder simplifies a governance structure that had grown increasingly complex as the three parties’ strategic interests diverged. Pfizer had retained certain put option rights over its ViiV Healthcare holding, and the liability associated with those rights had been a recurring feature of GSK’s consolidated accounts. The extinguishment of that put option liability at completion, with the fair value change recognised as an adjusting item in other operating income, will produce a one-off accounting benefit in the Q1 2026 results and removes an obligation that required recurring remeasurement at each reporting date.

The $250 million special dividend received by GSK, paid in British pounds, provides an immediate cash contribution that offsets a portion of the capital GSK may have deployed to support the transaction structure. More substantively, GSK retains 78.3% of an asset generating billions in HIV revenues annually, with a simplified two-shareholder structure that reduces governance friction and aligns both remaining parties around long-term HIV portfolio growth. For institutional investors focused on GSK’s capital return capacity, the cleaner ViiV Healthcare structure should reduce uncertainty around future distributions from this asset.

What does GSK’s current share price level and market positioning tell us about investor sentiment toward the ViiV Healthcare deal?

GSK’s NYSE-listed American depositary receipts were trading at approximately $54.43 at the time of completion, representing a meaningful recovery from the 52-week low of $32.38 and sitting well below the 52-week high of $61.70. On the London Stock Exchange, GSK shares were trading around 2,065 pence, within a 52-week range of 1,242.50 pence to 2,282.00 pence. The stock is currently trading near its 200-day moving average, a broadly neutral positioning that reflects a market still assessing the pace at which GSK’s HIV and broader specialty medicines franchise can offset the longer-dated patent pressure that is expected to begin materialising around 2028 on key HIV compounds.

Analyst consensus on GSK is split, with five buy-side recommendations against four sell calls and an average 12-month price target of around 2,032 pence on the London listing, slightly below current levels. Barclays has maintained a sell-side rating in recent months, reflecting concerns about pipeline execution and the competitive HIV landscape rather than structural concerns about ViiV Healthcare itself. The completion of the Pfizer exit is unlikely to be a near-term share price catalyst in isolation, but it removes a source of balance sheet uncertainty and signals that GSK is actively managing its asset portfolio with discipline ahead of the patent cycle headwinds ahead.

What are the longer-term implications for HIV drug development now that Pfizer is no longer a ViiV Healthcare shareholder?

The departure of Pfizer from ViiV Healthcare narrows the competitive intelligence sharing obligations that existed between the joint venture and one of the world’s largest pharmaceutical companies. Pfizer, while a passive minority investor with no operational role in ViiV Healthcare, nonetheless had access to financial information about the enterprise and a seat at certain shareholder meetings. With Pfizer now fully exited, ViiV Healthcare’s governance is cleaner and its two shareholders, GSK and Shionogi, share an unambiguous common interest in growing HIV revenues rather than managing competing priorities.

The HIV therapy landscape is moving toward longer-acting and potentially curative interventions, and both GSK and Shionogi have made explicit that investing in this direction is central to ViiV Healthcare’s strategy. With cabotegravir remaining a core asset and the pipeline extending toward next-generation long-acting combinations, the two-party ownership structure creates a more agile platform for making capital allocation decisions around clinical development and commercial infrastructure investment. The elimination of a third shareholder whose priorities lay elsewhere removes a potential source of governance friction at exactly the moment when ViiV Healthcare faces its most consequential competitive challenge from Gilead Sciences.

Key takeaways: What the ViiV Healthcare ownership restructure means for GSK, Shionogi, and the HIV therapy market

• GSK retains 78.3% of ViiV Healthcare after Pfizer’s full exit, securing majority control of one of pharma’s most profitable HIV franchises with revenues tracking toward £7 billion annually.
• Shionogi has more than doubled its ViiV Healthcare stake to 21.7% for $2.125 billion, a conviction bet on the long-acting HIV portfolio at a moment of peak competitive intensity from Gilead Sciences.
• Pfizer received $1.875 billion for its 11.7% holding, implying a ViiV Healthcare enterprise value of approximately $16 billion, broadly consistent with analyst estimates given the growth premium on long-acting injectables.
• The deal extinguishes the Pfizer put option liability from GSK’s balance sheet, removing a recurring accounting complexity and producing a one-off adjusting item in Q1 2026 results.
• GSK received a $250 million special dividend paid in GBP as part of the transaction structure, providing immediate cash flow alongside the balance sheet clean-up.
• Cabenuva generated approximately £1.4 billion in 2025 annual sales, accounting for 55% of ViiV Healthcare’s total HIV growth, validating the long-acting strategy that Shionogi’s capital commitment is premised on.
• Gilead Sciences’ twice-yearly lenacapavir represents the most significant competitive threat to ViiV Healthcare’s Apretude PrEP franchise; the dosing frequency differential is a key commercial battleground through 2026 and beyond.
• The simplified two-party shareholder structure reduces governance friction and aligns GSK and Shionogi around a single common objective: maximising ViiV Healthcare’s HIV franchise value ahead of patent headwinds expected from approximately 2028.
• GSK shares on the NYSE were trading around $54.43 at completion, within a 52-week range of $32.38 to $61.70; the transaction is not a near-term catalyst but reduces balance sheet uncertainty for institutional investors.
• Shionogi’s enlarged stake reinforces the Osaka-based company’s identity as a focused HIV specialist, with ViiV Healthcare distributions now representing a more meaningful component of its recurring revenue base.